About Us – Mounjaro News

About Mounjaro News

Clear, Simple & Evidence-Based Mounjaro News

MounjaroNews.com is an independent educational news site dedicated to clear, unbiased coverage of Mounjaro® (tirzepatide) and related topics. We translate new research, regulatory updates, and safety information into simple, trustworthy insights you can use.

Our Mission

Why Mounjaro News Exists

The world of Mounjaro and tirzepatide is evolving quickly. Our mission is to help readers stay informed with accurate, balanced, and up-to-date information so they can make confident, informed decisions.

Independent Reporting

We are not owned by pharma, manufacturers, or advertisers. Our coverage is independent, transparent, and free from commercial influence.

Patient Education

We break down complex medical and scientific information into simple, easy-to-understand explainers for everyday readers.

Research Summaries

We summarize the latest clinical studies, trials, and real-world evidence so you can stay ahead of important developments.

Safety First

We prioritise safety information and regulatory updates to help you stay aware of important warnings and guidance.

Our Focus

What We Cover

We focus on the topics that matter most to our readers:

FDA Updates: The latest approvals, label changes, warnings, and regulatory actions.

Research News: Summaries of clinical trials, studies, and scientific publications.

Safety Alerts: Important safety communications and potential side effects.

Diabetes & Weight Management: Evidence-based insights for managing type 2 diabetes and weight.

Patient-Friendly Explainers: Simple guides and FAQs to help you understand your options.

Lilly’s official patient material describes Mounjaro as a once-weekly pen injection and provides official use, dosing, storage, and side-effect information.